In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

After several severe RSV cases were reported in a pediatric trial of Moderna's vaccine, the FDA has partially paused testing ...

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug ...

The agency identified 20 cases of serious liver damage associated with Ocaliva in the latest setback for a drug once seen as a potential blockbuster.

Sometimes the most under-hyped sectors are the best places to build very large businesses,” said one venture investor who ...

Global strategic partner in healthcare, Avalere Health, is proud to announce the appointment of Amar Urhekar as its new Chief ...

The biotech halted dosing in two study arms after finding instances of pericardial effusion in testing of its drug, which analysts have viewed as a potential threat to Merck’s Winrevair.

Almac Clinical Technologies is a global provider of Interactive Response Technology (IRT) and expert consultancy for the biopharmaceutical industry, empowering trial sponsors to pro-actively manage ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...